Novus, Medical M&A Company Enters Medicinal Cannabis Industry
March 04 2014 - 5:10PM
Access Wire
MIAMI, FL / ACCESSWIRE / Mar 4, 2014 / Novus Acquisition &
Development Corp. (OTC Pink: NDEV) has formed a subsidiary called
Novus MMJ, Inc. known for its expertise in the medical marijuana
field (“MMJ or Cannabis”) to add to our health portfolio.
NDEV was approached by Healthcare executives to gain access to
an industry with an over a $6 billion market cap over the past 2
months. The investment community should know that NDEV business
model is seizing opportunities in the regulated MMJ industry. The
business model approach is primary development in Healthcare,
Pharma, Physicians Education, Compliance, Security/Law Enforcement
and the Business Development aspects. We will provide turnkey
operations through methods of acquiring real property, equipment,
Healthcare market positioning, Research and Development in Pharma
(cannabis compounding) and Intellectual Property then lease back to
the cultivators, dispensaries along with other ancillary business
products and services to assist MMJ licensors in their business
needs.
NDEV has initiated the following goals to be better
positioned to address the needs of the Medicinal Cannabis
industry:
- Create a board of advisors
- Finalize its Audit to become a reporting company for full
transparency and move to the bulletin board
- Procure and/or create federally recognized software to track
seed to sale and more
- Sign agreements with DNA Testing and Cannabis Compound
laboratories for product development
- Purchase land and develop growing facilities for leasing
purposes and potential R&D
To learn more details you can
visit: http://www.accesswire.com/uploads/mmj.pdf
About Novus
Novus is comprised of seasoned Wall Street veterans that have
focused its business model in the cannabis industry. Management and
its proposed future Board of Directors areas of expertise will
diversify in Healthcare, Physicians Education, Pharma R&D,
Compliance and Business Development. NDEV will work as an outside
developer and since it not Federally approved it will not
cultivate, handle, transport grow, extract, dispense put up for
sale, put on the market, vend, deliver, supply, circulate, trade,
cannabis or any substances that violate United States law or the
Controlled Substances Act, nor does it intend to do so in the
future and will continue to follow state and federal laws.
For investor Relations contact:
Bridgewater
Communications Group
Main Tel: (855) 4-BCG-INFO / (855) 422-4463
Email: info@bcginfo.com
Contact Novus
Gary F. Labrozzi, CEO
305-467-6699
Source: Novus Acquisition & Development Corp.
Novus Acquisition and De... (PK) (USOTC:NDEV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Novus Acquisition and De... (PK) (USOTC:NDEV)
Historical Stock Chart
From Feb 2024 to Feb 2025